Phase II study of S-1 plus irinotecan combined with bevacizumab as 2nd-line chemotherapy in patients with unresectable colorectal cancer, who had previously received oxaliplatin-based chemotherapy.
收藏NIAID Data Ecosystem2026-03-07 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2621739
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: CPT-11 150mg/m2 i.v. (day1) Bev 7.5mg/kg i.v. (day1) S-1 80mg/m2 p.o. (day1-14) to be repeated every 3 weeks
Primary outcome(s): Progression Free Survival
Study Design: Single arm Non-randomized
创建时间：
2011-08-15
